Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

NSE · ASTERDM

ASTERDM

HealthcareHealthcare Services₹63555 cr market cap
₹738.30 ▲ +1.0% today As of 19 Nov 2026
52-week low ₹537.9552-week high ₹869.70

-15.9% from the 52-week high · +35.9% above the low

Aster DM Healthcare Ltd. engages in the provision of healthcare solutions. The company is headquartered in Dubai, Karnataka and currently employs 30,330 full-time employees. The company went IPO on 2018-02-26. The Company’s segments include Hospitals, Clinics and Retail Pharmacies. The Hospitals segment comprises of hospitals and in-house pharmacies at the hospitals. The Clinics segment comprises of clinics and in-house pharmacies at the clinics. The Retail Pharmacies segment comprises standalone retail pharmacies and optical outlets. The firm also comprises healthcare consultancy services. Its geographical segments consist of gulf corporation council (GCC) States, including United Arab Emirates, Qatar, Oman, Kingdom of Saudi Arabia, Jordan, Kuwait, Bahrain, India and Rest of the world. The firm's healthcare services are offered under Aster, Medcare and Access brands. The firm operates over five medical centers, approximately six pharmacies, one full-fledged diagnostic center and a multispecialty Aster Hospital.

The short version. ASTERDM reported revenue of ₹2,829 crore for Sep 2026, up 136.3% from a year earlier. Net profit was ₹262 crore (up 138.2% year on year). Return on equity was 8.5% in Mar 2026. Promoter holding was 53.79% in Sep 2026, up 11.91 points over 8 quarters.

1 · The price

How has the stock traded?

ASTERDM trades 15.9% below its 52-week high and 35.9% above its 52-week low.

Change over period: —

1M+9.6%
3M-8.6%
6M-4.4%
1Y+7.3%

2 · The business

Is it growing?

Sales, year on year+136.3%

Sep 2026 revenue of ₹2,829 cr.

Profit, year on year+138.2%

Sep 2026 net profit of ₹262 cr.

Net margin9.3%

0.1 pts higher than a year earlier.

3-year growth-3.0% profit

Revenue compounded at -26.5% over the same 3 years.

Reported results · ₹ crore

Revenue and profit

Show the numbers

Quarterly

Sep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue28291311118211861197107810001050
Net profit2621614052110867957
Net margin %9.31.211.94.49.27.97.95.4
EPS (₹)3.010.312.711.012.121.651.581.14

Annual

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue4643413836991193310253860887387963
Net profit3885378129425526148277333
Net margin %8.4129.93.53.65.11.73.24.2
EPS (₹)7.49107.662.598.5110.532.965.546.59

3 · The quality

How well does it turn capital into profit?

Return on equity was 8.5% in Mar 2026; debt to equity is 0.15.

Profitability · 4 years

Returns and margins

Mar 2026Mar 2025Mar 2024Mar 2023
Return on equity %8.5156.92.89.6
Return on capital %10.210.72.28.4
EBITDA margin %20.820.116.213.7
Net margin %8.1125.43.53.5

Compound growth

Revenue vs profit

3 years5 years
Revenue CAGR-26.5%-11.2%
Profit CAGR-3.0%21.3%
Debt to equity0.15
Interest cover5.9x
Current ratio1.99
P/E ratio101.8

4 · The owners

Who holds it, and are they adding?

Promoter holding53.79%

Up 11.91 pts over 8 quarters.

Foreign institutions12.26%

Down 10.36 pts over 8 quarters.

Domestic institutions21.67%

Down 1.24 pts over 8 quarters.

Mutual fund schemes184

+41 versus the previous month.

Shareholding pattern (%)

Quarter by quarter

Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoter41.8841.8940.3940.3940.3940.3940.3953.79+11.91
FII22.6221.6619.6418.7218.4617.1810.5312.26-10.36
DII22.9124.5925.2826.3226.1227.5727.6521.67-1.24
Public12.3111.614.4414.3314.7914.6221.4212.17-0.14

Mutual fund holdings · Oct 2026

184 schemes hold this stock

143 the month before.

  • Groww BSE Hospitals ETF8.52% of NAV
  • Sundaram Long Term Tax Advantage Fund Series IV7.37% of NAV
  • Sundaram Long Term Micro Cap Tax Advantage Fund Series VI7.35% of NAV
  • Sundaram Long Term Micro Cap Tax Advantage Fund Series III7.08% of NAV
  • Sundaram Long Term Micro Cap Tax Advantage Fund Series IV7.04% of NAV
  • Sundaram Long Term Tax Advantage Fund Series III7.01% of NAV
  • Sundaram Long Term Micro Cap Tax Advantage Fund Series V6.89% of NAV
  • LIC MF HEALTHCARE FUND4.64% of NAV

See what mutual funds are buying

5 · The model view

What does our factor model say?

Factor scores, model flags and screen results for ASTERDM are part of the Wright portfolio review.

Run your free portfolio review

Watchouts

What to review

Model flags are shown inside the portfolio review, alongside your other holdings.

Model ratingLocked
Factor betaLocked
VolatilityLocked

Quick answers

Common questions about ASTERDM

What is the ASTERDM share price?

ASTERDM (ASTERDM) last closed at ₹738.30, up 1.0% on the day. Its 52-week range is ₹537.95 to ₹869.70.

What is the market cap of ASTERDM?

ASTERDM has a market capitalisation of about ₹63,555 crore. Its price-to-earnings ratio is 101.8.

How are ASTERDM's latest results?

ASTERDM reported revenue of ₹2,829 crore for Sep 2026, up 136.3% from a year earlier. Net profit was ₹262 crore (up 138.2% year on year). Return on equity was 8.5% in Mar 2026. Promoter holding was 53.79% in Sep 2026, up 11.91 points over 8 quarters.

Who owns ASTERDM?

As of Sep 2026, shareholding was: Promoter 53.79%, FII 12.26%, DII 21.67%, Public 12.17%.

How many mutual funds hold ASTERDM?

184 mutual fund schemes held ASTERDM in October 2026. That compares with 143 the month before.

Corporate actions

Recent dividends, bonuses and splits

  • 02 Apr 2026 · Interim Dividend - Rs. 3
  • 28 Aug 2025 · Final Dividend - Rs. 1
  • 10 Feb 2025 · Interim Dividend - Rs. 4
  • 22 Aug 2024 · Final Dividend - Rs. 2
  • 23 Apr 2024 · Special Dividend - Rs. 118

Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.